New Reports Surface About The SAPIEN Aortic Valve Replacement
By Adam Pick on November 17, 2011
In case you missed it… Some very interesting reports came out about the SAPIEN, a non-invasive aortic valve replacement for patients with aortic stenosis that just received FDA approval for inoperable patients, at the recent Transcatheter Cardiovascular Therapeutics conference in San Francisco.
- As reported in Medical News, two-year follow-up findings of the PARTNER trial indicate that transcatheter aortic valve implantation (TAVI) may be a better option than standard treatment. For more, click here.
- As reported at TheHeart.org, a study comparing the transapical approach for transcatheter aortic-valve implantation (TAVI) against conventional aortic-valve replacement surgery was stopped early due to an increase in adverse events, including an increased risk of major stroke and severe paravalvular leakage, in elderly patients eligible for surgery. For more, click here.
- As reported in Cardiovascular Business, the cost effectiveness of transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) depends on whether TAVI is performed via the femoral artery or transapically, through a small incision in the chest. For more, click here.
As always, I will continue to keep you updated on the latest news and reports regarding the advance of heart valve technologies — including the transcatheter based devices.
Keep on tickin!